LDS/Medical Tests/Paroxysmal Nocturnal Hemoglobinuria (PNH) (CD55, CD59), Flow, Blood

Paroxysmal Nocturnal Hemoglobinuria (PNH) (CD55, CD59), Flow, Blood

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a genetic disorder in which the Red Blood Cells (RBC) break down easily and early. As a result of the breakdown of RBCs, hemoglobin (the oxygen-carrying molecule contained within the RBC) is leaked into the blood and can also pass into the urine. This breakdown process can happen at all times of day, but is most noticeable at night or early morning due to the concentrated urine. The appearance of the urine as a dark brown color is typical. The genetic mutation associated with PNH is an X-linked defect in the PIG-A (phosphatidylinositol glycan-class A) gene. This mutation causes a deficiency in the production of GPI (Glycophosphatidylinositol) and GPI-anchored proteins including CD55 and CD59 red cell membrane antigens. The result of this mutation allows for a higher sensitivity to the effects of another blood protein system called complement, which can induce RBC destructive lysis. This can be especially problematic in PNH patients during an infection, surgery, or strenuous exercise.

PNH patients can also have platelet (the blood particles that help with clotting) abnormalities. All patients with PNH have bone marrow failure and pancytopenia is common at some point in their course. Some PNH patients develop aplastic anemia or myelodysplasia. Thrombosis (blood clots) and renal failure are the most common cause of death in PNH patients. Almost all patients show the presence of hemoglobin in the urine; however, this is not specific to PNH for diagnosis. Flow cytometry or fluorescein-labeled proaerolysin variant are considered the best diagnostic tests for PNH due to the sensitivity and specificity of the methods. If CD55 and CD59 are not found during analysis, this is considered diagnostic of PNH. There has been recent work in treating PNH with the monoclonal antibody eculizumab showing long term safety and efficacy.

  • Diagnose and monitor Paroxysmal Nocturnal Hemoglobinuria
  • Absent expression of CD55 and CD59 is diagnostic of PNH
  • Expression of either CD55 or CD59 is considered equivocal and should be considered for retest or PIG-A gene mutation

No expression of CD55 and CD59
 

 

 

Flow Cytometry assay (single-color) utilizing anti-CD55 and anti-CD59 monoclonal antibodies. Fluorescein-labeled proaerolysin variant (FLAER).

Whole Blood EDTA (Lavender), Heparin (Green) or ACD (Yellow). 

Stability

  • Ambient: 72 hours
  • Refrigerated: Unacceptable
  • Frozen: Unacceptable
PIG-A Gene Mutation, CBC, Coomb’s test, Flow Cytometry, Ham’s (acid hemolysin) Test, Hemoglobin, Hematocrit, Sucrose Hemolysis Test, Urinalysis including hemosiderin, Hemosiderin stain.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login